Chardan Capital Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)
Equities research analysts at Chardan Capital initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a report issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $50.00 price target on the stock. Chardan Capital’s price objective indicates a potential upside of 151.64% from the company’s previous […]
Equities research analysts at Chardan Capital initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a report issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $50.00 price target on the stock. Chardan Capital’s price objective indicates a potential upside of 151.64% from the company’s previous […]
